Purpose of Review <p>Pollen sensitization is a major cause of asthma and allergic rhinitis worldwide, creating a serious public health issue. There is a significant gap in effective care because most diagnostic and allergen immunotherapy (AIT) products come from North America and Europe. This focus overlooks the unique allergenic profiles in Asia, Africa, and other areas. This article looks at current allergy products, highlighting these global differences and the urgent need for a Global-Local strategy.</p> Recent Findings <p>Our review shows a lack of clinically significant allergenic plants, which leads to poor management and missed sensitizations. We identify “diagnostic blind spots,” such as bottlebrush plants that have no commercial tools available, and we note a significant gap between diagnosis and treatment. </p> Summary <p>A shift toward a Global-Local approach is necessary to create diagnostic panels and AIT products that reflect local plant life accurately. This change would meet the huge unmet needs of millions of patients globally and improve both treatment outcomes and diagnostic accuracy.</p>